All News
Depends on Where You’re Looking (8.9.2024)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.
Read Article
Romosozumab vs. Teriparatide in Postmenopausal Osteoporosis
The effectiveness and safety of romosozumab (ROMO) and teriparatide (TPTD) were compared in a clinical setting, and ROMO showed greater increases in BMD than TPTD after 12 months of therapy, along with a higher completion rate.
Lit review of ILD in anti-synthetase syndrome finds no conclusive evidence of effective treatment. 10 studies, 514 pts (68% female); Hi Res CT positive in 87% w/ 49% having NSIP pattern. 48% Jo-1+, 28% Ro52+. Low improvements w/ RTX (12%), CYC (17%). https://t.co/B7R0xQrUyw https://t.co/2hMzO8hyiV
Dr. John Cush RheumNow ( View Tweet)
Retrospective study from Univ of Tokyo on 194 Behcets dz (BD) pts, found 25% who developed intestinal BD (meanF/U 12 yrs). Use of #PPI significantly incr risk of intestinal BD (adj HR 2.48; vs non-PPI), w/ a confirmed duration/dose-dependent relationship. https://t.co/qFeS8svMLj https://t.co/KT8OBrY96S
Dr. John Cush RheumNow ( View Tweet)
Immune pathology of bursitis in rheumatic conditions - role of inflammation, degeneration, & mechanical stress. Cells and cytokines involved. Tenditis and tenosynovitis often coexist w/ bursitis https://t.co/fXf1LBTS4e https://t.co/LxmsIXhZaU
Links:
Dr. John Cush RheumNow ( View Tweet)
Anti-Ku + myositis: an acquired inflammatory protein-aggregate myopathy. 92% female, median age 56yrs w/ very hi CK levels, 31% have overlap w/ scleroderma (half of these have ILD). Path shows by myofiber necrosis, MHC-class I/II+, endomysial inflammation https://t.co/7HDUEPmbdi https://t.co/vnSjOph31G
Dr. John Cush RheumNow ( View Tweet)
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/5chrS3sW8i https://t.co/twSv4Zs9r3
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA: Trends in the Ranking of Leading Causes of Death—US, 2019-2023 https://t.co/RgGrYe0tbE https://t.co/SdMmadOD3S
Dr. John Cush RheumNow ( View Tweet)
3+ million persons died in USA in 2023. Overall age-adjusted death rate in 2023 was 6.1% lower than 2022. Overall death rate highest among non-Hispanic Blacks or African Americans. The number of COVID-19 deaths was 68.9% lower than in 2022 https://t.co/Oqgxcs4yUz https://t.co/lDn1PuEQ5Z
Dr. John Cush RheumNow ( View Tweet)
Finding Spondylitis Among Psoriasis, Uveitis and Colitis Patients
Maksymowych and colleagues have shown that screening patients with either psoriasis, iritis, or colitis may yield a surprising percentage meeting ASAS criterial for axSpA.
https://t.co/lVCdGnMVaT https://t.co/jFILeHrQXj
Dr. John Cush RheumNow ( View Tweet)
Relapses with RTX Maintenance in ANCA-associated Vasculitis
A real-world study on ΜPA and GPA patients found that RTX maintenance had a 25% relapse risk, with lower rates when combined with cyclophosphamide treatment.
https://t.co/bD6u5JWVqS https://t.co/CSotJt4in1
Dr. John Cush RheumNow ( View Tweet)
Study of 4378 pts COVID tested betw 2020-22, found low risk (3-4%)of myalgic encephalomyelitis/chronic fatigue syndr (ME/CFS) subsequent to SARS-CoV-2 infx, w/ no difference betw COVID test pos & neg. (OR 0.84; 0.42-1.67) Not supporting long COVID as FM? https://t.co/M0NWvuxT2n https://t.co/hoW5sVOYcN
Dr. John Cush RheumNow ( View Tweet)
Exploratory study of 22 RA pts w/ mod/severe periodontitis and RA. After periodontal Tx, only pts w/ severe (not moderate) periodontitis had significant reduction in DAS28 and CCP2 levels. Use periodontal Tx in RA management & T2T strategy? https://t.co/X7oXByzTnX https://t.co/b0vwTp4tfd
Dr. John Cush RheumNow ( View Tweet)
EU study of 1052 systemic sclerosis pts failed to show early immunosuppressive use (vs late) lowered ILD risk. Early Rx (Dz Dur < 3yrs) group (n=547, 52%) more male, diffuse Dz, 60% Rx w/ MTX (1.7% biologics); ILD in 47% after3.6yrs (HR 1.13;0.93–1.38) https://t.co/PtQlgyX0TE https://t.co/R7X3zvPvIg
Dr. John Cush RheumNow ( View Tweet)
Tick-borne diseases have increased in the last decade in the US, including Lyme disease (~476 000/yr), babesiosis, human granulocytic anaplasmosis (HGA), Rocky Mountain spotted fever, monocytic ehrlichiosis (HME), alpha gal allergy (red meat allergy) https://t.co/tl8qPyjU3Z https://t.co/AP0wglsJXM
Dr. John Cush RheumNow ( View Tweet)
The adipokine Resistin - predicts disease severity and survival in patients with pulmonary arterial hypertension. High resistin levels (>4.5ng/mL) in PAH assoc w/ older age, shorter 6-min walk, decr CV performance, incr death (HR 2.6) https://t.co/TUR4KnVsR9 https://t.co/rc6IMNWH4w
Dr. John Cush RheumNow ( View Tweet)
Prospective Vasculitis Study of Takayasu’s Arteritis - 236 pts, 92% women, mean age 36 yrs, Dz duration 2.6yrs. Damage present in >80% at baseline (75% vascular, 40+% cardiac), even with recent Dx and >40% pts accrue new, mainly disease-specific damage https://t.co/DKZQdH4HuZ https://t.co/LVjqAZYnOZ
Dr. John Cush RheumNow ( View Tweet)
Barriers to Treat-to-Target in Rheumatoid Arthritis
A systematic and scoping literature examined the Treat-to-target (T2T) approach to rheumatoid arthritis (RA), noting its implementation is suboptimal and finding many barriers to implementation.
https://t.co/CMEd62BfU0 https://t.co/YHQ408No4S
Dr. John Cush RheumNow ( View Tweet)
Economic, Personal Burden of RA: Maybe Not So Bad?
Data from a major federal survey indicate that people with RA don't pay massively more for healthcare than other folks, nor is their risk for functional deficits tremendously greater, researchers found.
https://t.co/ZFw7KZ0Wsb https://t.co/bO02YbzWvb
Dr. John Cush RheumNow ( View Tweet)
NEJM Clinical Images: Coup de Sabre (linear scleroderma) 70-year-old woman with a history of hypothyroidism presented to the dermatology clinic with a 1-year history of progressive indentation and darkening of the skin of her forehead
https://t.co/RiVNQiy5MM https://t.co/pxVEqBIUWP
Links:
Dr. John Cush RheumNow ( View Tweet)